Myelodysplastic Syndrome — Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
Citation(s)
A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome